The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety.
The anxiolytic properties of nabilone, a synthetic cannabinoid resembling the natural cannabinoids, were studied in 25 outpatients suffering from anxiety. The drug was compared with a placebo in a double-blind manner over a 28-day treatment period. Patients were seen weekly by the physician and were rated by the Hamilton Rating Scale for Anxiety and the Patient's Global Evaluation as well as by patient-rated evaluations. The results of the study showed a dramatic improvement in anxiety in the nabilone group when compared with placebo (P less than 0.001). Side effects reported were dry mouth, dry eyes, and drowsiness. Patients did not report any of the subjective "altered state" experience of marihuana.
D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents; D001008:Anxiety Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D013997:Time Factors
D014151:Anti-Anxiety Agents; D010919:Placebos; C011941:nabilone; D013759:Dronabinol